Press Releases June 4, 2026 04:01 PM

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

Praxis Precision Medicines to present corporate overview at Goldman Sachs 47th Annual Global Healthcare Conference

By Avery Klein PRAX

Praxis Precision Medicines, a CNS precision neuroscience biopharmaceutical company, announced it will present a corporate overview at the Goldman Sachs Global Healthcare Conference on June 8, 2026. The company focuses on developing therapies for CNS disorders using genetic insights and proprietary small molecule and antisense oligonucleotide platforms, with a diversified pipeline including late-stage candidates for movement disorders and epilepsy.

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
PRAX

Key Points

  • Praxis will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
  • The company develops therapies for CNS disorders using genetic insights and proprietary platforms, Cerebrum™ and Solidus™.
  • Praxis has a diversified CNS portfolio including four late-stage product candidates targeting movement disorders and epilepsy.

BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will be presenting a corporate overview at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 taking place in Miami, FL at the Loews Miami Beach Hotel on Monday, June 8, 2026 at 8:00am ET.

A live webcast of the event will be available through this link. A replay of the event will also be available on Praxis’ “Events and Presentations” website after each event for approximately 180 days.

About Praxis  
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and X/Twitter.


Risks

  • Clinical and regulatory risks linked to late-stage CNS drug candidates affecting product approval and commercial success.
  • Dependence on the efficacy of proprietary platforms (Cerebrum™ and Solidus™) to deliver effective therapies.
  • Market competition and potential challenges in commercializing novel CNS treatments.

More from Press Releases

LiqTech International Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Jun 4, 2026 Correction: Keystone Acquisition Corp. Announces Closing of $287.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option Jun 4, 2026 Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026